安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
- Gilead Sciences - Wikipedia
Gilead Sciences Gilead Sciences, Inc ( ˈɡɪliəd ) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir sofosbuvir and sofosbuvir
- Dear Gilead, Stop Being Greedy.
Gilead Sciences is blocking access to a twice-yearly injection (Lenacapavir) that can both treat HIV and prevent new infections Lenacapavir could become a cornerstone in controlling the global HIV epidemic — improving adherence, reducing transmission, and saving lives
- Gilead to Acquire Ouro Medicines in $2. 18B Deal, Expand Inflammation . . .
On March 23, The Wall Street Journal reported that Gilead Sciences, Inc (NASDAQ:GILD) plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2 18 billion
- Gilead boosts immunology pipeline with over $2 billion buyout of Ouro . . .
Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth more than $2 billion to expand its pipeline of immune disorder drugs
- Gilead Sciences Inc (GILD) Stock Price News - Google Finance
Get the latest Gilead Sciences Inc (GILD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions
- Gilead Sciences Gains an Opportunity for Immune System Reset With $1. 7B . . .
Gilead Sciences is acquiring Ouro Medicines, a startup developing T cell engagers for a range of autoimmune diseases Separately, Gilead is negotiating a deal with Galapagos to share in the
- Ouro Medicines sold to Gilead Sciences for $2. 18bn
Gilead Sciences has agreed to acquire biotech firm Ouro Medicines in a deal worth up to $2 18bn The deal will see Gilead bolster its cell therapy pipeline by acquiring a company focused on developing T cell engager therapies for autoimmune diseases
|
|
|